BLUE LION BIOTECH is partnered to offer new mechanism anti-microbial antibiotics technology that uses alternate mechanisms to kill bacteria or inhibit their growth. This will include multi-drug resistant bacteria, such as Methicillin Resistant Staphylococcus Aureus (MRSA) or Tuberculosis Bacillus (TB). It also includes microbes that can form resistant biofilms, e.g., Pseudomonas, as part of their disease-causing process and/or are biothreats such as Yersinia pestis, which causes bubonic plague.
The prevention of death and disability, the relief of pain and suffering, the restoration of functioning: these are the aims of regenerative medicine. Beyond its tangible benefits, regenerative health care touches on countless important and in some ways mysterious aspects of personal life. In recognition of these special features, Blue Lion Biotech recognizes the ethical and legal implications of marketing and representing the availability of biomedical services and specialty products.
This work is being done via an exclusive distributor agreement with Incell Corp. Incell has created an extensive collaborative network of companies, academic investigators and government agencies, including:
- UIW Feik School of Pharmacy
- Academic Centers
- Government Agencies
- Other Companies
- More to be added…..
All biomedical services are paid to Blue Lion Biotech on a commission referral basis.